|
16.12.2024 13:51:45
|
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 16 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
Under the programme initiated 11 November 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 3,136,206,122.30 in the period from 11 November 2024 to 3 February 2025.
Since the announcement 9 December 2024, the following transactions have been made:
| Number of B shares | Average purchase price | Transaction value, DKK | |
| Accumulated, last announcement | 1,614,979 | 1,208,671,173 | |
| 9 December 2024 | 77,000 | 787.38 | 60,627,879 |
| 10 December 2024 | 77,000 | 790.85 | 60,895,452 |
| 11 December 2024 | 77,000 | 783.61 | 60,337,748 |
| 12 December 2024 | 75,000 | 782.00 | 58,649,857 |
| 13 December 2024 | 75,000 | 762.70 | 57,202,647 |
| Accumulated under the programme | 1,995,979 | 1,506,384,757 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 23,343,636 B shares of DKK 0.10 as treasury shares, corresponding to 0.5% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 13 December 2024, Novo Nordisk has since 6 February 2024 repurchased a total 22,199,078 B shares at an average share price of DKK 827.52 per B share equal to a transaction value of DKK 18,370,178,634.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,
Facebook, Instagram, X, LinkedIn and
YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
| Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com | David Heiberg Landsted
+45 3077 6915 dhel@novonordisk.com |
| Sina Meyer +45 3079 6656 azey@novonordisk.com | Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com |
| Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
Company announcement no 97 / 2024
Attachments
Nachrichten zu Novo Nordisk
|
15:58 |
Anleger in Europa halten sich zurück: STOXX 50 notiert im Minus (finanzen.ch) | |
|
12:26 |
Zurückhaltung in Europa: STOXX 50 präsentiert sich am Mittag leichter (finanzen.ch) | |
|
11:41 |
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial (GlobeNewswire) | |
|
09:28 |
Angespannte Stimmung in Europa: STOXX 50 legt zum Handelsstart den Rückwärtsgang ein (finanzen.ch) | |
|
19.12.24 |
Schwacher Wochentag in Europa: STOXX 50 letztendlich im Minus (finanzen.ch) | |
|
19.12.24 |
Handel in Europa: STOXX 50 notiert am Nachmittag im Minus (finanzen.ch) | |
|
19.12.24 |
Börse Europa: STOXX 50 fällt mittags zurück (finanzen.ch) | |
|
19.12.24 |
Börse Europa: STOXX 50 schwächelt zum Start des Donnerstagshandels (finanzen.ch) |
Analysen zu Novo Nordisk
| 16:19 | Novo Nordisk Underperform | Bernstein Research | |
| 14:17 | Novo Nordisk Neutral | UBS AG | |
| 13:01 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 17.12.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 16.12.24 | Novo Nordisk Neutral | UBS AG |
Bitcoin: 150.000 USD Marke im 2025? | BX Swiss TV
Wird Bitcoin die 150.000 USD Marke nächstes Jahr erreichen und was heisst das kürzlich gesehen Allzeithoch für die Branche?
Im heutigen Experteninterview mit David Kunz, COO der BX Swiss spricht Sina Meier, Managing Director bei 2Shares über den Verlauf für Kryptowährungen des Jahres 2024.
Was dabei am besten lief, welche Auswirkungen institutionelle Anleger auf den Markt haben und welche neuen Innovationen man von 21Shares erwarten kann, erfahren Sie im heutigen Experteninterview.
👉🏽 Jetzt auch auf BXplus anmelden und von exklusiven Inhalten rund um Investment & Trading profitieren!
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| Novo Nordisk | 76.88 | 0.00% |
|
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
Hexensabbat: SMI und DAX schliessen deutlich schwächer -- Asiens Börsen letztlich mit AbschlägenDer heimische und deutsche Aktienmarkt gaben zum Wochenschluss deutlich nach. Die US-Börsen verbuchen am Freitag Zuschläge. Die asiatischen Indizes präsentierten sich am Freitag im Minus.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |